MMS Blog

  • 4 Essentials to Colleague Recruitment and Retention in Pharma

    Posted on 2/15/2013 12:01 PM

    Employee turnover is costly. There is no industry in which that assertion holds more truth than the biotech industry. In this industry, the average cost of replacing an employee is roughly 50% more than the runner-up aerospace/defense industry.1 The obvious implication here is that turnover, particularly at a biotech company or a clinical research organization (CRO), should be kept to a minimum. Retaining quality employees should be a priority for any company (for many reasons, financial and oth

    View Post

  • Pharmacovigilance: Recent Developments & Future Perspectives

    Posted on 1/17/2013 12:06 PM

    The development of new and effective medicinal products makes a positive contribution to the health and well-being of individuals. However, there is a need to improve pharmacovigilance (PV) systems to more effectively monitor and take action on safety issues associated with medicines to enhance their contribution to public health. This article looks at the current trends driving the development of PV strategies in order to achieve this aim. Factors behind the development of current trends Glob

    View Post

  • Accelerated Approval of Oncology Drugs: Overnight Successes

    Posted on 12/20/2012 9:33 AM

    The Newsweek headline on May 27, 2001 announced “A Cure for Cancer?” Just weeks before this headline, the United States Food and Drug Administration (FDA) announced the accelerated approval of a new powerful anti-cancer drug after a review period of only two and a half months, making it the fastest FDA-approved cancer drug in history. Scientists and physicians were thrilled that one of the first targeted tyrosine kinase inhibitors, Gleevec, demonstrated efficacy in patients with chronic myeloge

    View Post

  • Clinical Trial Disclosure: More “FDA” Needed in Past & Present Acts?

    Posted on 11/29/2012 9:54 AM

    Federal mandates calling for transparency of clinical trial information have been in place in the United States since 1997, but a recent move will finally give the current FDA (Food and Drug Administration) law some teeth to enforce compliance. In September, the US Department of Health & Human Services (HHS) transferred authority from HHS control to the FDA to oversee information that is filed to ClinicalTrials.gov (“clinical trial registry data bank”), and seek out those who fail to file, o

    View Post

  • How to Build a Document Review Team: A Medical Writing Guide

    Posted on 10/11/2012 10:45 AM

    Whether it’s the completion of a clinical study report (CSR) for a clinical trial, or the completion of a submission document for a drug development program, medical writing represents the culmination of many people’s work over the course of many years. Due to the number of stakeholders involved across multiple functional areas, medical writing tends to be a consensus‑driven process, representing many contributor’s thoughts and ideas. Building the right review team can significantly contribute t

    View Post

  • Clinical Disclosure Reporting: Are You Prepared to Meet the Expanding Requirements?

    Posted on 9/7/2012 10:54 AM

    A group of House Democrats led by Congressman Edward Markey (D-Mass.) on Aug. 2 introduced the Trial and Experimental Studies Transparency (TEST) Act of 2012 (H.R. 6272), legislation that "updates and expands the clinical trial registry data bank—ClinicalTrials.gov—with stronger reporting requirements," according to a press release dated that same day (1). This proposed legislation is yet another step to address the increasing demand for greater transparency of clinical trial information. As we

    View Post

  • What NOT to Do When Writing a Clinical Study Report

    Posted on 8/17/2012 11:52 AM

    Clinical study reports (CSRs) describe the methods and results for each individual clinical trial. CSRs are included in the clinical part of the submission, so it’s important they are well written and easy to understand. As almost every clinical trial protocol is unique, the CSRs that describe their results will also need to be uniquely crafted. There are ICH guidelines (ICH E3) about what to do in the CSR but here are a couple of informal tips about what NOT to do when writing a CSR: Ignore th

    View Post

  • Setting Ground Rules for Medical Writing Document Review

    Posted on 8/8/2012 12:01 PM

    A medical writer often has to be a jack of all trades in order to ensure accurate, on-time completion of clinical documents. Document review provides a critical opportunity for the medical writer to elicit value-added review from team members. The medical writer can lead strategically by clarifying team members’ roles and responsibilities, setting clear expectations for reviewers, and setting “ground rules” for document reviewers at the outset of the project. The below are suggestions for medica

    View Post

Regulatory Submission Support Based on Strong Science and Strength of Process. We Do Data Best!

Contact Us Today!